Literature DB >> 27358027

Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease.

Bryna S M Chow1, Terri J Allen2.   

Abstract

Angiotensin II (Ang II) is well-considered to be the principal effector of the renin-angiotensin system (RAS), which binds with strong affinity to the angiotensin II type 1 (AT1R) and type 2 (AT2R) receptor subtype. However, activation of both receptors is likely to stimulate different signalling mechanisms/pathways and produce distinct biological responses. The haemodynamic and non-haemodynamic effects of Ang II, including its ability to regulate blood pressure, maintain water-electrolyte balance and promote vasoconstriction and cellular growth are well-documented to be mediated primarily by the AT1R. However, its biological and functional effects mediated through the AT2R subtype are still poorly understood. Recent studies have emphasized that activation of the AT2R regulates tissue and organ development and provides in certain context a potential counter-regulatory mechanism against AT1R-mediated actions. Thus, this review will focus on providing insights into the biological role of the AT2R, in particular its actions within the renal and cardiovascular system.
© 2016 The Author(s). published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  AT2 receptor; AT2R agonism; cardiovascular; compound 21; kidney

Mesh:

Substances:

Year:  2016        PMID: 27358027     DOI: 10.1042/CS20160243

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  23 in total

Review 1.  Unravelling the Lesser Known Facets of Angiotensin II Type 1 Receptor.

Authors:  Mayank Chaudhary; Shashi Chaudhary
Journal:  Curr Hypertens Rep       Date:  2017-01       Impact factor: 5.369

2.  Targeting AT2 receptors in renal disease.

Authors:  Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2021-05-03

3.  Angiotensin receptor expression revealed by reporter mice and beneficial effects of AT2R agonist in retinal cells.

Authors:  Amrisha Verma; Ping Zhu; Annette de Kloet; Eric Krause; Colin Sumners; Qiuhong Li
Journal:  Exp Eye Res       Date:  2019-08-23       Impact factor: 3.467

4.  Angiotensin II type 1 receptor gene polymorphism and serum angiotensin-converting enzyme level in Egyptian children with systemic lupus erythematosus.

Authors:  Rasha Mohamed Saleh Shoaib; Ayman Hammad; Sohier Yahia; Afaf Elsaid; Camelia Adly Abdel-Malak
Journal:  Clin Rheumatol       Date:  2018-08-09       Impact factor: 2.980

Review 5.  AT1 receptor signaling pathways in the cardiovascular system.

Authors:  Tatsuo Kawai; Steven J Forrester; Shannon O'Brien; Ariele Baggett; Victor Rizzo; Satoru Eguchi
Journal:  Pharmacol Res       Date:  2017-05-17       Impact factor: 7.658

Review 6.  Update on angiotensin AT2 receptors.

Authors:  Robert M Carey
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-03       Impact factor: 2.894

Review 7.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

Review 8.  Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.

Authors:  Carlos M Ferrario; Adam E Mullick
Journal:  Pharmacol Res       Date:  2017-05-29       Impact factor: 7.658

9.  Renal AT2 Receptors Mediate Natriuresis via Protein Phosphatase PP2A.

Authors:  Brandon A Kemp; Nancy L Howell; John J Gildea; Susanna R Keller; David L Brautigan; Robert M Carey
Journal:  Circ Res       Date:  2021-11-19       Impact factor: 17.367

10.  Angiotensin II Receptor Blockers but Not Angiotensin-Converting Enzyme Inhibitors Are Associated With a Reduced Risk of Acute Kidney Injury After Major Surgery.

Authors:  Shao-Yu Yang; Tao-Min Huang; Tai-Shuan Lai; Nai-Kuan Chou; Chun-Hao Tsao; Yi-Ping Huang; Shuei-Liong Lin; Yung-Ming Chen; Vin-Cent Wu
Journal:  Front Pharmacol       Date:  2021-04-23       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.